Affordable Malaria Vaccine: A New Hope for Vulnerable Children

Global vaccine alliance Gavi and Unicef announced a 25% price reduction for the R21 malaria vaccine, produced by the Serum Institute of India. This decrease will facilitate broader vaccine access for children in low-income countries. The new cost per dose is set at $2.99, down from approximately $4.

In a strategic move to enhance global health outcomes, Gavi and Unicef have orchestrated a pivotal agreement to lower the cost of a new malaria vaccine.

The Serum Institute of India will supply the R21 vaccine at a 25% reduced price, bringing the per-dose cost down to $2.99. This price adjustment aims to expand access to the vaccine amidst tightening international aid budgets.

The initiative underscores a commitment to protecting vulnerable children in impoverished regions, leveraging both international collaboration and innovative funding strategies to fight malaria.